- Home
- BZAI vs SGMT Comparison
BZAI vs SGMT Comparison
Compare BZAI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BZAI | SGMT |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | 232 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.2M | 238.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | BZAI | SGMT |
|---|---|---|
| Price | $2.20 | $6.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.33 | ★ $29.71 |
| AVG Volume (30 Days) | ★ 1.5M | 630.6K |
| Earning Date | 02-15-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,857,000.00 | N/A |
| Revenue This Year | $2,317.12 | N/A |
| Revenue Next Year | $250.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 655.31 | N/A |
| 52 Week Low | $1.70 | $1.73 |
| 52 Week High | $19.25 | $11.41 |
Technical Indicators
Market Signals| Indicator | BZAI | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 51.38 |
| Support Level | $2.07 | $5.43 |
| Resistance Level | $2.18 | $6.63 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 81.82 | 66.55 |
Price Performance
Historical ComparisonAbout BZAI Blaize Holdings Inc.
Blaize Holdings Inc provides a customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.